Abbott's 2026 guidance cut driven by diabetes and electrophysiology, RBC says
FROM THE WIRE · FINANCE.YAHOO.COM
Abbott Laboratories' (ABT) 2026 guidance cuts were driven by headwinds related to its diabetes and e PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishA guidance cut at a large healthcare company can weigh on the stock and the medtech sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Abbott's 2026 guidance cut is linked to headwinds in diabetes.
- 02The electrophysiology portfolio also contributed to the revision, according to RBC.
- 03The full article is available only to premium subscribers.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets